San Antonio carries a health burden that no major American city wants: an estimated 17% of Bexar County adults have diagnosed Type 2 diabetes — nearly double the national average of roughly 9%. Approximately 72% of adults are overweight or obese, compared to 42% nationally. An estimated 700,000 San Antonio residents have prediabetes — a reversible metabolic condition that, without effective intervention, progresses to diabetes in a significant fraction of cases. For years, the answer to these statistics was a combination of lifestyle counseling, older oral medications, and weekly injectable drugs that many patients found inconvenient or inaccessible due to cost. That landscape has now fundamentally changed.
In January 2026, Novo Nordisk launched the Wegovy pill — the first oral GLP-1 receptor agonist for obesity treatment in U.S. history. The once-daily pill contains semaglutide — the same active ingredient as the injectable Wegovy and Ozempic — and in the OASIS 4 Phase 3 clinical trial, produced a mean weight loss of 16.6% at 64 weeks, comparable to injectable Wegovy's performance. One in three patients achieved at least 20% weight loss. The self-pay price is $149 per month — significantly lower than most injectable GLP-1 alternatives. For San Antonio, one of the most diabetes-burdened cities in the United States, these numbers represent the most significant shift in obesity treatment access since the introduction of the first injectable semaglutide.
